New drug combo aims to stop liver Cancer's return after surgery
NCT ID NCT07475026
Summary
This study is testing whether giving two drugs, tislelizumab and lenvatinib, before surgery can help people with liver cancer that can be removed by surgery but is likely to come back. The goal is to see if this treatment can lower the chance of the cancer returning and help patients live longer. About 198 participants will be randomly assigned to receive either the drug combination or standard care before their operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.